Reuters logo
2 个月前
BRIEF-Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic NSCLC
2017年6月22日 / 晚上9点54分 / 2 个月前

BRIEF-Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic NSCLC

June 22 (Reuters) - Novartis Ag

* Novartis combination targeted therapy tafinlar + mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)

* Approval provides first targeted treatment in U.S. specifically for BRAF V600E mutation-positive metastatic NSCLC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below